Patents by Inventor Ayumu Niida
Ayumu Niida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11518763Abstract: A compound represented by the following formula (I): wherein each symbol in the formula is as described herein or a salt thereof has an NRF2 activating activity, and is expected to be useful as a preventive or therapeutic agent for diseases associated with oxidative stress, in particular, hepatic disease (for example, non-alcoholic steatohepatitis (NASH)), cardiovascular disease (for example, heart failure or pulmonary arterial hypertension), lung disease (for example, chronic obstructive pulmonary disease (COPD)), kidney disease (for example, chronic kidney disease (CKD) or acute kidney injury (AKI)), central nervous system disease (for example, Parkinson's disease), mitochondrial disease (for example, Friedreich motor ataxia, mitochondrial myopathy), inflammatory disease (for example, multiple sclerosis (MS), inflammatory bowel disease (IBD)), sickle cell disease, cancer, or the like.Type: GrantFiled: December 4, 2019Date of Patent: December 6, 2022Assignee: SCOHIA PHARMA, INC.Inventors: Shigemitsu Matsumoto, Ryoma Hara, Naoyoshi Noguchi, Hideto Fukushi, Ayumu Niida, Satoshi Sasaki, Minoru Ikoma, Toshitake Kobayashi, Tsuyoshi Maekawa
-
Publication number: 20220135638Abstract: The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A341-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-P2 (SEQ ID NO: 4), or a salt thereof, wherein each symbol is as defined herein, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as provided in SEQ ID NOs: 4-569 disclosed in PCT/JP2018/013540.Type: ApplicationFiled: September 24, 2019Publication date: May 5, 2022Inventors: Hiroshi IMOTO, Mari ADACHI, Yoko KANEMATSU, Taiji ASAMI, Ayumu NIIDA, Naoki NISHIZAWA, Derek Cecil COLE, Mack FLINSPACH, Nick SCORAH, Abhijit Suresh BHAT
-
Publication number: 20220119391Abstract: Compounds represented by the following formula (I): wherein each symbol in the formula is as described herein, or a salt thereof, and compositions comprising the same, and methods of using the same as an NRF2 activator and/or a preventive or therapeutic agent for diseases associated with oxidative stress, in particular, hepatic disease (for example, non-alcoholic steatohepatitis (NASH)), cardiovascular disease (for example, heart failure or pulmonary arterial hypertension), lung disease (for example, chronic obstructive pulmonary disease (COPD)), kidney disease (for example, chronic kidney disease (CKD) or acute kidney injury (AKI)), central nervous system disease (for example, Parkinson's disease), mitochondrial disease (for example, Friedreich motor ataxia, mitochondrial myopathy), inflammatory disease (for example, multiple sclerosis (MS), inflammatory bowel disease (IBD)), sickle cell disease, cancer, or the like.Type: ApplicationFiled: December 4, 2019Publication date: April 21, 2022Applicant: SCOHIA PHARMA, INC.Inventors: Shigemitsu MATSUMOTO, Ryoma HARA, Naoyoshi NOGUCHI, Hideto FUKUSHI, Ayumu NIIDA, Satoshi SASAKI, Minoru IKOMA, Toshitake KOBAYASHI, Tsuyoshi MAEKAWA
-
Publication number: 20210403420Abstract: The present invention provides a benzoic acid ester compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. A compound represented by the formula (I) or a salt thereof has an enteropeptidase inhibitory effect and is useful as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like: [in the formula, each symbol is as defined in the specification].Type: ApplicationFiled: August 26, 2019Publication date: December 30, 2021Inventors: Ryoma HARA, Kohei ASANO, Ayumu NIIDA, Shizuo KASAI, Tsuyoshi MAEKAWA
-
Patent number: 11174301Abstract: The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P2?? (I) wherein each symbol is as defined herein.Type: GrantFiled: August 29, 2019Date of Patent: November 16, 2021Assignee: Takeda Pharmaceutical Company LimitedInventors: Taiji Asami, Naoki Nishizawa, Ayumu Niida, Yoko Kanematsu, Mari Adachi, Shiro Takekawa, Tomoko Morimoto
-
Publication number: 20200140505Abstract: The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P2?? (I) wherein each symbol is as defined herein.Type: ApplicationFiled: August 29, 2019Publication date: May 7, 2020Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMTEDInventors: TAIJI ASAMI, NAOKI NISHIZAWA, AYUMU NIIDA, YOKO KANEMATSU, MARI ADACHI, SHIRO TAKEKAWA, TOMOKO MORIMOTO
-
Patent number: 10501516Abstract: The present invention relates to a peptide compound that may be useful in the treatment or prophylaxis of obesity, diabetes and the like. More specifically, the present invention relates to a peptide compound represented by the formula (I): P1-Tyr-Aib-Glu-Gly-Thr-?-MePhe-Thr-Ser-Asp-Lys(-Gly-Gly-Gly-Gly-RA10)-A11-A12-Aib-Leu-A15-Lys-Gln-A18-Gln-Iva-Glu-Phe-Val-Arg-His-Leu-Leu-Asn-Lys-Aib-Thr-Arg-Gln-Arg-A35-NH2 wherein each symbol is as defined in the specification, and the treatment or prophylaxis of obesity, diabetes and the like using the peptide compound.Type: GrantFiled: May 23, 2017Date of Patent: December 10, 2019Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Taiji Asami, Ayumu Niida
-
Patent number: 10435445Abstract: The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. (I) P1-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13- A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25- A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37- A38-A39-A40-P2 wherein each symbol is as defined herein.Type: GrantFiled: March 30, 2018Date of Patent: October 8, 2019Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Taiji Asami, Naoki Nishizawa, Ayumu Niida, Yoko Kanematsu, Mari Adachi, Shiro Takekawa, Tomoko Morimoto
-
Publication number: 20190202883Abstract: The present invention relates to a peptide compound that may be useful in the treatment or prophylaxis of obesity, diabetes and the like. More specifically, the present invention relates to a peptide compound represented by the formula (I): P1-Tyr-Aib-Glu-Gly-Thr-?-MePhe-Thr-Ser-Asp-Lys(-Gly-Gly-Gly-Gly-RA10)-A11-A12-Aib-Leu-A15-Lys-Gln-A18-Gln-Iva-Glu-Phe-Val-Arg-His-Leu-Leu-Asn-Lys-Aib-Thr-Arg-Gln-Arg-A35-NH2 wherein each symbol is as defined in the specification, and the treatment or prophylaxis of obesity, diabetes and the like using the peptide compound.Type: ApplicationFiled: May 23, 2017Publication date: July 4, 2019Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Taiji ASAMI, Ayumu NIIDA
-
Publication number: 20180298070Abstract: The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P2 ??(I) wherein each symbol is as defined herein.Type: ApplicationFiled: March 30, 2018Publication date: October 18, 2018Applicant: Takeda Pharmaceutical Company LimitedInventors: Taiji Asami, Naoki Nishizawa, Ayumu Niida, Yoko Kanematsu, Mari Adachi, Shiro Takekawa, Tomoko Morimoto
-
Patent number: 10087229Abstract: The present invention provides a novel peptide compound having an activating action on GLP-1 receptors and GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a partial sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-Aib-Glu-Gly-Thr-alphaMePhe-Thr-Ser-Asp-Tyr-A11-A12-A13-Leu-Asp-A16-A17-Ala-Gln-A20-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-A29 (I) wherein each symbol is as defined herein.Type: GrantFiled: May 27, 2014Date of Patent: October 2, 2018Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Taiji Asami, Ayumu Niida
-
Publication number: 20160052988Abstract: The present invention provides a novel peptide compound having an activating action on GLP-1 receptors and GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a partial sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-Aib-Glu-Gly-Thr-al-phaMePhe-Thr-Ser-Asp-Tyr-A11-A12-A13-Leu-Asp-A16-A17-Ala-Gln-A20-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-A29 (I) wherein each symbol is as defined herein.Type: ApplicationFiled: May 27, 2014Publication date: February 25, 2016Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Taiji ASAMI, Ayumu NIIDA
-
Patent number: 9260500Abstract: The present invention aims to provide a peptide having a superior Y2 receptor agonist action and useful as an agent for the prophylaxis or treatment of obesity and the like. A peptide represented by the formula: P1—X1-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-NH2 wherein each symbol is as described in the specification, or a salt thereof.Type: GrantFiled: July 1, 2010Date of Patent: February 16, 2016Assignee: Takeda Pharmaceutical Company LimitedInventors: Taiji Asami, Naoki Nishizawa, Ayumu Niida, Yusuke Adachi
-
Patent number: 9200051Abstract: The present invention provides a novel peptide compound having an activating action on GLP-1 receptors and GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a partial sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-Aib-Glu-Gly-Thr-?MePhe-Thr-Ser-Asp-Tyr-A11-A12-A13-Leu-Asp-A16-A17-Ala-Gln-A20-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-A29 SEQ ID NO: 1 (I) wherein each symbol is as defined herein.Type: GrantFiled: May 27, 2014Date of Patent: December 1, 2015Assignee: Takeda Pharmaceutical Company LimitedInventors: Taiji Asami, Ayumu Niida
-
Publication number: 20140357552Abstract: The present invention provides a novel peptide compound having an activating action on GLP-1 receptors and GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a partial sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. (I) P1-Tyr-Aib-Glu-Gly-Thr-?MePhe-Thr-Ser-Asp-Tyr- A11-A12-A13-Leu-Asp-A16-A17-Ala-Gln-A20-Glu- Phe-Val-Lys-Trp-Leu-Leu-Lys-A29 wherein each symbol is as defined herein.Type: ApplicationFiled: May 27, 2014Publication date: December 4, 2014Applicant: Takeda Pharmaceutical Company LimitedInventors: Taiji ASAMI, Ayumu NIIDA
-
Publication number: 20120172293Abstract: The present invention aims to provide a peptide having a superior Y2 receptor agonist action and useful as an agent for the prophylaxis or treatment of obesity and the like. A peptide represented by the formula: P1-X1-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-NH2 wherein each symbol is as described in the specification, or a salt thereof.Type: ApplicationFiled: July 1, 2010Publication date: July 5, 2012Inventors: Taiji Asami, Naoki Nishizawa, Ayumu Niida, Yusuke Adachi
-
Patent number: 8183212Abstract: The present invention provides a compound represented by the following formula (1); wherein R1 is an aryl group etc.; R2 is —CO—NH— etc.; R3 is a methyl group having an aromatic group or a cycloalkyl group; R4 is a hydrogen atom etc.; R5 is a methyl group having an aromatic group; and R6 is an amino group or an N-alkyl substituted amino group, having a low-molecular weight and a superior GPR54 agonist activity, and a pharmaceutical composition containing the compound.Type: GrantFiled: October 24, 2006Date of Patent: May 22, 2012Assignees: Kyoto University, Takeda Phamaceutical Company LimitedInventors: Nobutaka Fujii, Shinya Oishi, Kenji Tomita, Ayumu Niida
-
Publication number: 20100160241Abstract: The present invention provides a compound represented by the following formula (1); wherein R1 is an aryl group etc.; R2 is —CO—NH— etc.; R3 is a methyl group having an aromatic group or a cycloalkyl group; R4 is a hydrogen atom etc.; R5 is a methyl group having an aromatic group; and R6 is an amino group or an N-alkyl substituted amino group, having a low-molecular weight and a superior GPR54 agonist activity, and a pharmaceutical composition containing the compound.Type: ApplicationFiled: October 24, 2006Publication date: June 24, 2010Applicant: Kyoto UniversityInventors: Nobutaka Fujii, Shinya Oishi, Kenji Tomita, Ayumu Niida